Non-Hodgkin's Lymphoma

Bexxar Highly Effective as First-Line Treatment

Published in Blood Weekly, June 8th, 2000

A radioactive antibody compound known as Bexxar produced tumor shrinkage in 97% of 76 previously untreated patients with advanced-stage, low-grade non-Hodgkin's lymphoma (NHL) in a new study at the University of Michigan Comprehensive Cancer Center.

Most notably, 76% of patients achieved a complete remission, with no sign of cancer. In addition, 84% of patients with evidence of lymphoma at the molecular level at the start of the trial achieved molecular remission for as long as three years with the treatment. Molecular remissions were determined by polymerase chain reaction (PCR) technology.

These promising results, from the first completed study...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2000-06-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry